In India’s rapidly urbanising metros, from Delhi to Bengaluru, life moves fast. Unfortunately, so do lifestyle-related ...

Menopause can feel like one big balancing act. Between managing your hormone levels and symptoms like hot flashes, night ...

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs to curb their off-label use for weight loss and preserve supply for people who are diabetic.

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...

Tirzepatide also acts on another naturally occurring hormone system called GIP, also known to suppress appetite. The mechanism through which these drugs impact appetite is multifaceted.

New research compared the effect of semaglutide vs. tirzepatide on weight loss over a 72 week period. Here's what the study found, and what a doctor has to say about it.

Tirzepatide, sold under the name Zepbound, activates two hormone receptors—GLP-1 and GIP—while semaglutide (Wegovy) only targets GLP-1. Both of these hormones help reduce appetite and regulate ...